Zacks Investment Research on MSN5d
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite SuccessImmunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia ...
Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...
Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...
Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...
Clinical Trials Arena on MSN6d
Immunovant will not seek approval for MG therapy, despite hitting endpointsThe company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...
Immunovant (IMVT) reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study ...
The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.
Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...
Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...
Batoclimab, subcutaneous formulation, offers the potential for at-home administration, improving patient convenience and ...
Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia gravis (MG) and initial results from Period 1 of a mid-stage study of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback